HC Wainwright Predicts Dare Bioscience Q1 Earnings

Dare Bioscience, Inc. (NASDAQ:DARE) – HC Wainwright issued their Q1 2027 earnings estimates for shares of Dare Bioscience in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst D. Tsao forecasts that the biotechnology company will post earnings per share of ($0.07) for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Dare Bioscience’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Dare Bioscience’s Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.05) EPS and FY2030 earnings at $6.27 EPS.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. Dare Bioscience had a negative return on equity of 748.30% and a negative net margin of 803.80%.The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.00 million.

A number of other analysts have also recently commented on DARE. Benchmark restated a “buy” rating on shares of Dare Bioscience in a research report on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dare Bioscience in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded Dare Bioscience to a “hold” rating in a research note on Saturday, May 23rd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Dare Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Dare Bioscience Stock Performance

NASDAQ DARE opened at $0.77 on Monday. The company has a market capitalization of $11.58 million, a PE ratio of -1.10 and a beta of 1.08. The business’s fifty day moving average is $1.70 and its 200 day moving average is $1.86. Dare Bioscience has a fifty-two week low of $0.75 and a fifty-two week high of $3.78.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. raised its holdings in Dare Bioscience by 810.6% during the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 13,650 shares during the period. LPL Financial LLC purchased a new stake in shares of Dare Bioscience during the fourth quarter worth about $28,000. Finally, Virtu Financial LLC purchased a new stake in shares of Dare Bioscience during the third quarter worth about $37,000. Institutional investors own 6.70% of the company’s stock.

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.